The application of Synchrotron X-ray micro-tomography in insect morphology

Die herkömmliche Methode der Untersuchung anatomischer Verhältnisse bei Insekten ist die manuelle Präparation und das Erstellen von Schnittserien eines eingebetteten Objektes in zwei, besser drei orthogonalen Raumrichtungen (frontal, axial und sagittal). Diese Schnitte werden dann spezifisch angefärbt und über Zeichnungen und / oder Fotographien ausgewertet. Mit speziellen zeichnerischen Verfahren oder mittels Graphikprogrammen können daraus 3D-Objekte „rekonstruiert“ werden. Eine neue vielversprechende Methode in der Insektenmorphologie ist die (phasenverstärkte) Synchrotron Mikro-Röntgentomographie. Ähnlich wie etwa bei den von Hörnschemeyer et al. (2002) genutzten Desktopgeräten wird hier mit relativ geringem Zeitaufwand der Vergleich kompletter „virtueller“ Schnittserien auch einer größeren Anzahl von Taxa, wie sie zum Beispiel für vergleichend-morphologische evolutionsbiologische Studien erforderlich sind, ermöglicht. Man erhält mittels der Tomographie-Datensätze die Möglichkeit, beliebige Schnittrichtungen am Computer zu bearbeiten und auszuwerten. Die Methode arbeitet zerstörungsfrei und ist somit auch für Museumsleihgaben oder seltene Einzelfunde geeignet.The (synchrotron-based) method of computer tomography is a non-invasive technique novel to insect morphology. It provides the researcher with the opportunity to investigate virtual serial sections through millimeter-sized objects of interest without destroying them. Here, we explain the principle of the technique and provide two illustrative examples. The first example relates to the muscles of the head and the structure of the inner head skeleton (tentorium) of Gyrophaena fasciata (Marsham) (Coleoptera, Staphylinidae: Aleocharinae). It is shown that SR-μCT is a useful technique to track muscles within the head and also to graphically represent the results. Moreover, it is demonstrated that the inner head skeleton elements can be three-dimensionally modeled and visualized. Our second example refers to the hind leg of Altica sp. (Coleoptera, Chrysomelidae: Alticini), in which details of the jumping mechanism could be further elucidated

Efficacy and tolerability of a 12-week combination chemotherapy followed by lomustine consolidation treatment in canine B- and T-cell lymphoma

BACKGROUND: High-grade lymphoma in dogs is a chemotherapy-responsive neoplasia with remission rates exceeding 80% under combination chemotherapy protocols. Usually these protocols are intensive and 24 + weeks. The objective of the present study was to investigate if a shorter protocol combined with an oral lomustine maintenance treatment (3 × in 8 weeks) would present an acceptable result, both for B- and T-cell lymphomas, and for the different types of lymphomas normally encountered in private veterinary practice. RESULTS: 144 dogs entered the study. Lymphoma types included multicentric (n = 123), alimentary (n = 13), miscellaneous (n = 7), and mediastinal lymphoma (n = 1). Overall response rate was 83.3% (B-cell: 86.6%, T-cell: 79.4%). Complete remission (CR) was achieved in 72.2% (B-cell: 77.3%, T-cell: 67.6%) and partial remission (PR) in 11.1% (B-cell: 9.3%, T-cell: 11.8%) of the dogs. Median duration of first CR amounted to 242 days (B-cell: 263 d, T-cell: 161 d). Median survival in dogs with CR was 374 days (B-cell: 436 d, T-cell: 252 d), and median overall survival time was 291 days (B-cell: 357d, T-cell: 210d). Immunophenotype demonstrated an independent significant influence on duration of remission and survival in the whole group. Findings of splenic and hepatic cytology were not significant associated with patient outcome. Treatment was well tolerated; the majority of adverse events were classified as grade 1 or 2. CONCLUSIONS: Short-term chemotherapy followed by lomustine consolidation leads to compara-ble remission and survival times compared to conventional protocols with cyclophosphamide, doxorubicin, vincristine and prednisolone with acceptable toxicosis in dogs with both B-cell and T-cell lymphoma

Feasibility and Efficacy of Accelerated Weekly Concomitant Boost Postoperative Radiation Therapy Combined with Concomitant Chemotherapy in Patients with Locally Advanced Head and Neck Cancer

Background: The aim of this study was to assess feasibility and efficacy of weekly concomitant boost accelerated postoperative radiation therapy (PORT) with concomitant chemotherapy (CT) in patients with locally advanced head and neck cancer (LAHNC). Methods and Materials: Conformal or intensity-modulated 66-Gy RT was performed in 5.5weeks in 40 patients. Cisplatin was given at days 1, 22, and 43. Median follow-up was 36months. Results and Discussion: Grade 3 mucositis, dysphagia, and erythema was observed in ten (25%), nine (23%), and six (13%) patients, respectively. Grade 3 or more anemia was observed in two (6%) patients, and leukopenia in five (13%) patients. No grade 3 or 4 thrombocytopenia was observed. Grade 3 nephrotoxicity was observed in one patient (3%). No treatment-related mortality was observed. Grade 2 or more xerostomia and edema were observed in ten (25%) and one (3%) patient, respectively. Locoregional relapse occurred in eight patients, and seven patients developed distant metastases. Median time to locoregional relapse was 6months. Three-year overall, disease-free survival, and locoregional control rates were 63%, 62%, and 81%, respectively. Multivariate analysis revealed that the only prognostic factor was nodal status. Conclusion: Reducing overall treatment time using accelerated PORT/CT by weekly concomitant boost (six fractions per week) combined with concomitant cisplatin CT is easily feasible with acceptable morbidit

Modeling the natural gas knocking behaviour using gas-phase infrared spectra and multivariate calibration

[Abstract] To assess the knocking properties of natural gas (NG) when it is used as fuel for vehicles is vital to optimize the design and functioning of their motors. Analytical efforts in this field are needed as the engines used to define it empirically are not available anymore, and existent mathematical algorithms yield different accuracy. The hybridization of gas-phase infrared spectrometry and partial least squares multivariate regression is presented first time to address the determination of the methane number (MN) of NG samples. It circumvents the need for the previous knowledge of the NG composition required to apply dedicated equations. The use of true NG samples to develop the models is also quite new in the field. Proof-of-concept studies were made with synthetic spectra and, then, a collection of liquefied NG samples for which MN values were computed by the National Physics Laboratory algorithm (NPL) from their sample composition were used to develop operative models. Additional validation was made with a collection of synthetic standard mixtures prepared for two European projects (EMRP LNG II and EMPIR LNG III) whose service methane numbers (SMN) were measured with an engine. The FTIR-PLS approach yielded statistically unbiased predictions with average standard errors around 0.4% MN when compared to the NPL-MN and SMN values, and standard deviations of the means ca. 1% MN. The approach is fast, cost effective as it involves standard instrumentation, and can be considered compliant with the green chemistry principles.This work is part of the EMPIR 16ENG09 project ‘Metrological support for LNG and LBG as transport fuel (LNG III)’. This project has received funding from the EMPIR programme co-financed by the Participant States and from the European Union's Horizon 2020 Research and Innovation programme. The authors from TU Braunschweig would like to thank IAV, Mahle, MAN Truck & Bus and Motortech for their support in preparing the test engine. The Group of Applied Analytical Chemistry of the University of A Coruña acknowledges Mestrelab, Reganosa and Naturgy for hiring its services for FTIR method developmentFinanciado para publicación en acceso aberto: Universidade da Coruña/CISU

Identification of genetic variants associated with Huntington's disease progression: a genome-wide association study

Background Huntington's disease is caused by a CAG repeat expansion in the huntingtin gene, HTT. Age at onset has been used as a quantitative phenotype in genetic analysis looking for Huntington's disease modifiers, but is hard to define and not always available. Therefore, we aimed to generate a novel measure of disease progression and to identify genetic markers associated with this progression measure. Methods We generated a progression score on the basis of principal component analysis of prospectively acquired longitudinal changes in motor, cognitive, and imaging measures in the 218 indivduals in the TRACK-HD cohort of Huntington's disease gene mutation carriers (data collected 2008–11). We generated a parallel progression score using data from 1773 previously genotyped participants from the European Huntington's Disease Network REGISTRY study of Huntington's disease mutation carriers (data collected 2003–13). We did a genome-wide association analyses in terms of progression for 216 TRACK-HD participants and 1773 REGISTRY participants, then a meta-analysis of these results was undertaken. Findings Longitudinal motor, cognitive, and imaging scores were correlated with each other in TRACK-HD participants, justifying use of a single, cross-domain measure of disease progression in both studies. The TRACK-HD and REGISTRY progression measures were correlated with each other (r=0·674), and with age at onset (TRACK-HD, r=0·315; REGISTRY, r=0·234). The meta-analysis of progression in TRACK-HD and REGISTRY gave a genome-wide significant signal (p=1·12 × 10−10) on chromosome 5 spanning three genes: MSH3, DHFR, and MTRNR2L2. The genes in this locus were associated with progression in TRACK-HD (MSH3 p=2·94 × 10−8 DHFR p=8·37 × 10−7 MTRNR2L2 p=2·15 × 10−9) and to a lesser extent in REGISTRY (MSH3 p=9·36 × 10−4 DHFR p=8·45 × 10−4 MTRNR2L2 p=1·20 × 10−3). The lead single nucleotide polymorphism (SNP) in TRACK-HD (rs557874766) was genome-wide significant in the meta-analysis (p=1·58 × 10−8), and encodes an aminoacid change (Pro67Ala) in MSH3. In TRACK-HD, each copy of the minor allele at this SNP was associated with a 0·4 units per year (95% CI 0·16–0·66) reduction in the rate of change of the Unified Huntington's Disease Rating Scale (UHDRS) Total Motor Score, and a reduction of 0·12 units per year (95% CI 0·06–0·18) in the rate of change of UHDRS Total Functional Capacity score. These associations remained significant after adjusting for age of onset. Interpretation The multidomain progression measure in TRACK-HD was associated with a functional variant that was genome-wide significant in our meta-analysis. The association in only 216 participants implies that the progression measure is a sensitive reflection of disease burden, that the effect size at this locus is large, or both. Knockout of Msh3 reduces somatic expansion in Huntington's disease mouse models, suggesting this mechanism as an area for future therapeutic investigation

Efficacy and tolerability of a 12-week combination chemotherapy followed by lomustine consolidation treatment in canine B- and T-cell lymphoma

BACKGROUND: High-grade lymphoma in dogs is a chemotherapy-responsive neoplasia with remission rates exceeding 80% under combination chemotherapy protocols. Usually these protocols are intensive and 24 + weeks. The objective of the present study was to investigate if a shorter protocol combined with an oral lomustine maintenance treatment (3 × in 8 weeks) would present an acceptable result, both for B- and T-cell lymphomas, and for the different types of lymphomas normally encountered in private veterinary practice. RESULTS: 144 dogs entered the study. Lymphoma types included multicentric (n = 123), alimentary (n = 13), miscellaneous (n = 7), and mediastinal lymphoma (n = 1). Overall response rate was 83.3% (B-cell: 86.6%, T-cell: 79.4%). Complete remission (CR) was achieved in 72.2% (B-cell: 77.3%, T-cell: 67.6%) and partial remission (PR) in 11.1% (B-cell: 9.3%, T-cell: 11.8%) of the dogs. Median duration of first CR amounted to 242 days (B-cell: 263 d, T-cell: 161 d). Median survival in dogs with CR was 374 days (B-cell: 436 d, T-cell: 252 d), and median overall survival time was 291 days (B-cell: 357d, T-cell: 210d). Immunophenotype demonstrated an independent significant influence on duration of remission and survival in the whole group. Findings of splenic and hepatic cytology were not significant associated with patient outcome. Treatment was well tolerated; the majority of adverse events were classified as grade 1 or 2. CONCLUSIONS: Short-term chemotherapy followed by lomustine consolidation leads to compara-ble remission and survival times compared to conventional protocols with cyclophosphamide, doxorubicin, vincristine and prednisolone with acceptable toxicosis in dogs with both B-cell and T-cell lymphoma

Enterococci in orthopaedic infections: Who is at risk getting infected?

Some orthopaedic patients might be at risk for enterococcal infections and might benefit from adapted perioperative prophylaxis